EP3 Stock Overview
Develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
OraSure Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.68 |
| 52 Week High | US$5.10 |
| 52 Week Low | US$2.48 |
| Beta | 0.77 |
| 1 Month Change | -12.42% |
| 3 Month Change | -29.47% |
| 1 Year Change | -47.45% |
| 3 Year Change | -52.98% |
| 5 Year Change | -82.37% |
| Change since IPO | -51.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| EP3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 1.1% | 0.7% |
| 1Y | -47.5% | -11.2% | 12.8% |
Return vs Industry: EP3 underperformed the German Medical Equipment industry which returned -11.6% over the past year.
Return vs Market: EP3 underperformed the German Market which returned 12.9% over the past year.
Price Volatility
| EP3 volatility | |
|---|---|
| EP3 Average Weekly Movement | 9.8% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: EP3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EP3's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 501 | Carrie Eglinton Manner | www.orasure.com |
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company’s products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples.
OraSure Technologies, Inc. Fundamentals Summary
| EP3 fundamental statistics | |
|---|---|
| Market cap | €201.78m |
| Earnings (TTM) | -€17.27m |
| Revenue (TTM) | €164.59m |
1.2x
P/S Ratio-11.7x
P/E RatioIs EP3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EP3 income statement (TTM) | |
|---|---|
| Revenue | US$185.83m |
| Cost of Revenue | US$105.07m |
| Gross Profit | US$80.76m |
| Other Expenses | US$100.26m |
| Earnings | -US$19.50m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 43.46% |
| Net Profit Margin | -10.49% |
| Debt/Equity Ratio | 0% |
How did EP3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/02 19:23 |
| End of Day Share Price | 2025/04/30 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OraSure Technologies, Inc. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Karen Koski | BTIG |
| Mark Massaro | Canaccord Genuity |